Scope
The IAP chapter emphasizes clinical assessment and supportive management of childhood bronchiolitis. Feeding, breathing, oxygenation, vulnerability and the family’s ability to obtain care guide admission and monitoring. Its discussion of selected inhaled treatments is explicitly qualified by limited consensus.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Assess severity and vulnerability
- Ask about household viral illness, prematurity, daycare attendance, congenital heart disease, crowding and passive smoke exposure during the outpatient assessment. [1]
- Admit children with moderate-to-severe bronchiolitis. Additional reasons include age under 6 weeks, prematurity, congenital heart disease, chronic lung disease, immunodeficiency or neuromuscular disease, and caregivers unable to follow care instructions or living far from help. [1]
- Diagnosis is clinical. Routine blood testing, chest radiography and virological studies are not indicated for routine uncomplicated assessment; investigations can be useful when the diagnosis is uncertain. [1]
- Consider alternative explanations such as pneumonia, asthma presenting for the first time, foreign-body aspiration, airway malformations or compression, aspiration pneumonia and gastro-oesophageal reflux. [1]
Support breathing and hydration
- Nurse the child propped up and use nasal saline to relieve nasal blockage. Supportive positioning, airway comfort, hydration and oxygen are the foundation of care. [1]
- The chapter indicates supplemental oxygen when room-air SpO2 is below 92%. High-flow nasal oxygen may be used as required, and CPAP is indicated for impending respiratory failure. [1]
- Use orogastric feeding when oral intake is poor. Give intravenous fluids to children who are dehydrated. [1]
Keep limited-consensus therapies selective
- The chapter says hypertonic saline or nebulized adrenaline might shorten admission in selected hospitalized infants, while noting that broad consensus is lacking. These are not presented as mandatory routine treatment. [1]
- If the chapter’s adrenaline option is selected, it describes a 1:1000 solution at 0.1–0.3 mL/kg per dose, maximum 5 mL, diluted with 2–3 mL normal saline and nebulized every 6 hours. The limited-consensus qualification applies to this regimen. [1]
- Beta-2 agonists may be continued only when a response is observed after the first dose. The chapter’s key messages state that bronchodilators, steroids, antivirals and montelukast have no routine role. [1]
- The treatment section lists antivirals, oral bronchodilators and ipratropium bromide as having no management role. [1]
Check stability before discharge
- The chapter’s discharge criteria require stable normal vital parameters, adequate oral intake and room-air oxygen saturation above 92% for at least 4 hours. Its criteria are attributed to NICE guidance published in 2015. [1]
Prevent transmission and consider RSV immunoprophylaxis
- Use meticulous hand hygiene to prevent transmission. Encourage exclusive breastfeeding, which the chapter describes as protective against viral infections. [1]
- The chapter describes giving nirsevimab intramuscularly before the first RSV season during an infant’s first year of life. The weight-based dose table has an unstated boundary, so this summary does not reproduce it as a complete dosing rule. [1]
- For children with risk factors, a second-season nirsevimab dose may be given while younger than 2 years: 200 mg as two intramuscular injections of 100 mg at different sites. The chapter permits administration with other childhood vaccines. [1]
- Palivizumab is described for high-risk infants at 15 mg/kg intramuscularly each month, beginning before RSV season and continuing monthly through the season. [1]
- The chapter describes maternal RSV vaccination with a single intramuscular dose at 32–36 weeks during RSV season. Its statement about Indian availability reflects the document’s publication context and is not a current availability check. [1]
Limitations and use
- This summary follows the IAP chapter’s stated thresholds; it does not establish that its cited NICE discharge criteria remain the latest NICE recommendation. The nirsevimab weight bands are written as below and above five kilograms, with the exact boundary unstated. Figures and graphical algorithms without readable source content are not reconstructed. The chapter does not supply all product-label eligibility criteria, availability updates or prescribing precautions.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Acute Bronchiolitis - Clinical Approach and Management Updates
Selected recommendation material consulted
Publication details
- Issuing organisation
- IAP
- Resource type
- Practice guideline · House clinical summary
- Source setting
- India
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.